School of Medicine
Showing 21-40 of 62 Results
Paul George, MD, PhD
Assistant Professor of Neurology and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsCONDUCTIVE POLYMER SCAFFOLDS FOR STEM CELL-ENHANCED STROKE RECOVERY:
We focus on developing conductive polymers for stem cell applications. We have created a microfabricated, polymeric system that can continuously interact with its biological environment. This interactive polymer platform allows modifications of the recovery environment to determine essential repair mechanisms. Recent work studies the effect of electrical stimulation on neural stem cells seeded on the conductive scaffold and the pathways by which it enhances stroke recovery Further understanding the combined effect of electrical stimulation and stem cells in augmenting neural repair for clinical translational is a major focus of this research going forward.
BIOPOLYMER SYSTEMS FOR NEURAL RECOVERY AND STEM CELL MODULATION:
The George lab develops biomaterials to improve neural recovery in the peripheral and central nervous systems. By controlled release of drugs and molecules through biomaterials we can study the temporal effect of these neurotrophic factors on neural recovery and engineer drug delivery systems to enhance regenerative effects. By identifying the critical mechanisms for stroke and neural recovery, we are able to develop polymeric technologies for clinical translation in nerve regeneration and stroke recovery. Recent work utilizing these novel conductive polymers to differentiate stem cells for therapeutic and drug discovery applications.
APPLYING ENGINEERING TECHNIQUES TO DETERMINE BIOMARKERS FOR STROKE DIAGNOSTICS:
The ability to create diagnostic assays and techniques enables us to understand biological systems more completely and improve clinical management. Previous work utilized mass spectroscopy proteomics to find a simple serum biomarker for TIAs (a warning sign of stroke). Our study discovered a novel candidate marker, platelet basic protein. Current studies are underway to identify further candidate biomarkers using transcriptome analysis. More accurate diagnosis will allow for aggressive therapies to prevent subsequent strokes.
Assistant Professor of Pediatrics (Critical Care)
Current Research and Scholarly InterestsMy laboratory is focused on understanding the cellular mechanisms which mediate end-organ failure in pediatric sepsis. Our current work focuses on determining the role of altered mitochondrial dynamics in sepsis-induced multi-organ dysfunction syndrome (MODS). Specifically, we focus on understanding the mechanisms that mediate derangements in mitochondrial fission and autophagy in sepsis.
Yang Hu, MD, PhD
Associate Professor of Ophthalmology
Current Research and Scholarly InterestsThe ultimate goal of the laboratory is to develop efficient therapeutic strategies to achieve CNS neural repair, through promoting neuroprotection, axon regeneration and functional recovery.
More specifically, we study retinal ganglion cell (RGC) and optic nerve in various optic neuropathies including traumatic, glaucomatous and inflammatory optic nerve injuries to fully understand the molecular mechanisms of CNS neurodegeneration and axon regeneration failure.
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406
Executive Adminstrator, SPARK at Stanford
Current Role at StanfordProgram Administrator, SPARK at Stanford
Executive Admin to:
Daria Mochly-Rosen, Professor
Kevin V. Grimes, Professor - Teaching
Department of Chemical & Systems Biology
Jeewon Sylvia Kim
Program Manager, SPARK at Stanford
Current Role at StanfordProgram manager for SPARK Translational Science Program overseeing educational seminar series, managing projects and facilitating SPARK global operations.
Bruce Koch, Ph.D.
Director, High-Throughput Screening
Current Role at StanfordHead, ChEM-H/CSB High Throughput Screening Knowledge Center (HTSKC)
Staff Co-lead, IMA HTS Module
Adviser to the SPARK Program
Y. Joyce Liao, MD, PhD
Professor of Ophthalmology and of Neurology
Current Research and Scholarly InterestsIschemic optic neuropathy
Stem cell transplantation
Eye movement disorders
Joanna E. Liliental, PhD
Director, TRAM, M-TRAM, TASC, Med/TRAM
Current Role at StanfordExecutive Director, Master's in TRAM (M-TRAM)
Director, Translational Applications Service Center (TASC)
Associate Director, Translational Research and Applied Medicine (TRAM) Program
Senior Research Scientist, Stanford School of Medicine
Instructor of University Courses: MED221,MED121, MED212A
Member, Stanford Cancer Institute
Wendy Liu, MD, PhD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsDr. Liu's research interests include the role of mechanosensation in the eye as it relates to the pathophysiology of glaucoma, with the goal of finding new druggable targets in glaucoma treatment.
Basic Life Science Research Scientist, Genetics
BioXin Liu is a postdoctoral Research Scientist in the Department of Genetics at Stanford University. Xin holds a PhD in Chemistry from the University of Michigan, Ann Arbor. Her basic research interests include RNA and protein biochemistry, enzymology, cancer immunology, and autoimmune disease. She has published papers in several prestigious journals in the field of biochemistry, including Nature Communications, Journal of American Chemical Society, and Nucleic Acids Research. The highlight of her multidisciplinary research includes the development of high-throughput enzymatic methods to discover anti-microbial agents and to reveal mechanisms behind human mitochondrial diseases, as well as innovative applications of genome engineering and machine-learning to decode principles of RNA editing in human cells. Her current research focuses on the mechanistic study of innate immune pathways.
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
Professor of Biomedical Data Science and, by courtesy, of Epidemiology
Current Research and Scholarly InterestsBiostatistics, clinical trials, statistical evaluation of medical diagnostic tests, radiology, osteoporosis, meta-analysis, medical decision making
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine